Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations

NCT02608125 is registered in ClinicalTrials.gov with Principia Biopharma, a Sanofi Company as lead sponsor.

NCT NCT02608125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02608125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations
Lead sponsor
Principia Biopharma, a Sanofi Company
Phase
Phase 1
Overall status
Terminated
Start date
October 28, 2015
Completion date
June 23, 2020
Enrollment
45 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial carcinoma & renal pelvis & ureter, solid tumors